TumorPrint’ project for the printing of human cancer models receives EU funding

Written by Georgi Makin

CELLINK (Gothenburg, Sweden) have been awarded a €2.5 million grant from the European Commission to develop and commercialize their project, ‘TumorPrint’, for the benefit of research into cancer tumors and their cellular reactions to different pharmaceutical compounds. CELLINK (Gothenburg, Sweden) have been awarded a €2.5 million grant from the European Union to develop and commercialize their project, ‘TumorPrint’. CELLINK will be funding the project with an additional €1 million. The aim of the project is to develop and commercialize a bioprinting platform for the specialized printing of human cancer tumors. This is set to include bioinks as well as specially...

To view this content, please register now for access

It's completely free